Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Similar presentations


Presentation on theme: "Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,"— Presentation transcript:

1 Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial  Prof Tim Meyer, MBBS, Richard Fox, MSc, Yuk Ting Ma, MBChB, Paul J Ross, MBBS, Martin W James, MBBS, Richard Sturgess, MBBS, Clive Stubbs, MSc, Deborah D Stocken, PhD, Lucy Wall, MBBS, Anthony Watkinson, MD, Nigel Hacking, MBBS, T R Jeffry Evans, MBBS, Peter Collins, MBBS, Richard A Hubner, PhD, David Cunningham, MD, John Neil Primrose, MBBS, Philip J Johnson, MBBS, Daniel H Palmer, MBBS  The Lancet Gastroenterology & Hepatology  Volume 2, Issue 8, Pages (August 2017) DOI: /S (17) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

2 Figure 1 Trial profile The Lancet Gastroenterology & Hepatology 2017 2, DOI: ( /S (17) ) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

3 Figure 2 Kaplan-Meier plots for survival outcomes
(A) Progression free survival; (B) overall survival; (C) time to progression; and (D) overall survival by HAP score. HAP=hepatoma arterial-embolisation prognostic. HR=hazard ratio. The Lancet Gastroenterology & Hepatology 2017 2, DOI: ( /S (17) ) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

4 Figure 3 Subgroup analyses of (A) progression-free survival and (B) overall survival for known prognostic factors HAP=hepatoma arterial-embolisation prognostic. ECOG PS=Eastern Cooperative Oncology Group performance status. AFP=α-fetoprotein levels. *Not pre-planned. The Lancet Gastroenterology & Hepatology 2017 2, DOI: ( /S (17) ) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

5 Figure 4 Restricted cubic splines fit to quality-of-life scales
Quality of life was measured through EORTC QLQ-C30 and QLQ-HCC18. All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high or healthy level of functioning, but a high score for a symptom scale represents a high level of symptomatology or problems. Functioning scales were (A) role, and (B) social. Symptom scales were (C) appetite loss, (D) diarrhoea, and (E) nutrition. The Lancet Gastroenterology & Hepatology 2017 2, DOI: ( /S (17) ) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions


Download ppt "Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,"

Similar presentations


Ads by Google